Shots:

• The P-III ATLAS (n= 616) & FLAIR (n= 566) studies involve assessing of Rilpivirine + Cabotegravirin vs oral HIV therapies in virally suppressed HIV patients
• The ATLAS (NCT02951052) & FLAIR (NCT02938520) studies resulted in meeting its 1EPs i.e- plasma HIV-1 RNA ≥50 copies per milliliter (c/mL) & patients with virologic failure- non-inferior to Triumeq respectively @48wks.
• Janssen’s Rilpivirine & and ViiV Healthcare's Cabotegravir (q4w- inj.) is a long-acting combination therapy codeveloped under Jan-2016 agreement b/w the companies

Ref: Janssen | Image: Janssen